



## **Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference**

February 11, 2022

WILMINGTON, Del., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (NASDAQ: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18 at 1:40 p.m. ET.

A live webcast of the presentation can be accessed by visiting the "Investors" page under the "[Events & Presentation](#)" section of the Prelude website, where a replay of the presentation will be available for a limited time.

### **About Prelude Therapeutics**

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative, potential best-in-class molecules targeting critical cancer cell pathways involved in cancer pathogenesis. Prelude's initial clinical candidates, PRT543 and PRT811, are potent, selective, oral PRMT5 inhibitors in Phase 1 development for the treatment of advanced solid tumors, primary and secondary CNS cancers and select myeloid malignancies. PRT1419, a potent and selective MCL1 inhibitor, is in Phase 1 development for patients with relapsed/refractory hematologic malignancies and solid tumors. PRT2527, a highly selective CDK9 inhibitor, is anticipated to begin Phase 1 clinical development by year-end as a monotherapy in patients with selected solid tumors. In addition, the Company's pipeline includes PRT-SCA2, a SMARCA2 protein degrader, PRT-K4, a highly selective kinase inhibitor, and additional discovery stage programs.

### **Investor Contacts:**

Stacey Jurchison  
Executive Director, Corporate Affairs  
[sjurchison@preludetx.com](mailto:sjurchison@preludetx.com)

Melissa Forst  
Argot Partners  
212.600.1902  
[prelude@argotpartners.com](mailto:prelude@argotpartners.com)

### **Media Contact:**

Paige Donnelly  
Argot Partners  
212.600.1902  
[prelude@argotpartners.com](mailto:prelude@argotpartners.com)